Last Updated: 11 Nov 2024
Executive Summary
Maravai Lifesciences Holdings Inc. (MRVI) is a life sciences company that offers products for drug development, diagnostics, vaccines, and human disease research. The company has a market capitalization of $1.28 billion and is headquartered in San Diego, California. MRVI's latest stock price is $5.08.
Company Overview
Maravai Lifesciences is a leading provider of products and services to the life sciences industry. The company's products include cell culture media, reagents, and instruments used in drug discovery, diagnostics, and research. Maravai Lifesciences also provides contract research services to pharmaceutical and biotechnology companies.
The company's customers include pharmaceutical and biotechnology companies, academic institutions, and government agencies. Maravai Lifesciences has a global reach and sells its products in over 100 countries.
Fundamental Analysis
Maravai Lifesciences has a strong financial position. The company has a healthy balance sheet with $229.6 million in cash and equivalents and no debt. Maravai Lifesciences also has a strong cash flow from operations, which provides the company with the financial flexibility to invest in new products and services.
The company's revenue has grown steadily in recent years. In 2023, Maravai Lifesciences reported revenue of $276.9 million, up from $254.3 million in 2022. The company's earnings per share have also grown in recent years. In 2023, Maravai Lifesciences reported EPS of -$1.67, up from -$1.89 in 2022.
Technical Analysis
Maravai Lifesciences' stock price has been trending down in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is also below 50, indicating that the stock is oversold.
Short Term Outlook
The short-term outlook for Maravai Lifesciences is mixed. The company's financial position is strong, but the stock price has been trending down. The stock's RSI is also below 50, indicating that the stock is oversold.
Long Term Outlook
The long-term outlook for Maravai Lifesciences is positive. The company is a leader in the life sciences industry and has a strong financial position. The company's products and services are in high demand, and the company is well-positioned to continue to grow in the future.
Analyst Recommendations
The majority of analysts have a buy rating on Maravai Lifesciences. The average analyst target price is $9.72, which represents a potential upside of 91.3% from the current stock price.
